Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New program aims to help breast cancer patients talk about what matters most

NCT ID NCT06795529

Symptom relief Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a five-session palliative care program called TARGET-PC for people with metastatic breast cancer and their caregivers. The goal is to help patients talk with their doctors about their goals and values for care, and to have those preferences documented. The study will compare this program to enhanced usual care in 400 patients across multiple sites.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
palliative care program (TARGET-PC)
What this could lead to
If successful, this could show that a structured palliative care program helps patients with metastatic breast cancer have earlier and better conversations with their doctors about what matters most in their care.
What could go wrong
This is a behavioral intervention trial, not a drug study, so it won't directly treat the cancer. The benefits may be modest and depend on how well patients and clinicians engage with the program.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 400 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

Mar 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Patient Inclusion Criteria: * age ≥18 years * diagnosed with metastatic breast cancer * within 8 weeks of the oncology visit at which they were identified as having an eligible Epic EOL Care Index (≥ 15) * functioning independently per an Eastern Cooperative Oncology Group performance status ≤2 * receiving their cancer care at one of the participating institutions * able to complete questionnaires in English or Spanish Patient Exclusion Criteria: * received outpatient palliative care visit within the last six months * enrolled in hospice services * diagnosed with a comorbid condition that impairs their ability to understand study procedures and/or consent for the trial as per the report of the oncology clinician(s) Caregiver Inclusion Criteria: * age ≥18 years * identified by the patient as a family member or friend who is primarily involved in their care * able to complete questionnaires in English or Spanish

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metastatic breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metastatic breast cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Duke University

    RECRUITING

    Durham, North Carolina, 54677, United States

  • Massachusetts General Hospital

    RECRUITING

    Boston, Massachusetts, 02465, United States

  • University of Pennsylvania

    RECRUITING

    Philadelphia, Pennsylvania, 46205, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.